Shandong Xinhua Pharmaceutical Gets Marketing Go-Ahead for Reflux Disease Drug in China

MT Newswires Live09-02

Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) has obtained marketing approval for its esomeprazole magnesium drug from China's National Medical Product Administration, a Monday bourse filing said.

Esomeprazole magnesium is used to treat reflux disease, according to the pharmaceutical company.

Hong Kong- and China-listed shares of the company closed 1% and 2% lower, respectively, on Monday.

Price (HKD): $5.28, Change: $-0.060, Percent Change: -1.12%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment